Multiple sclerosis begins when the body’s immune system, which normally fights infections, turns against the brain and spinal cord. Immune cells cross into the central nervous system, attack the fatty insulation around nerve fibers, and set off a chain of damage that disrupts how nerves communicate. The process is not a single event but a cascade: barrier breach, inflammation, myelin loss, energy failure inside exposed nerve fibers, and eventually permanent nerve death. What makes MS especially difficult to pin down is that this cascade behaves differently in different people and at different stages of the disease.
Breaking Through the Blood-Brain Barrier
Your brain has a built-in security system called the blood-brain barrier. It lines the blood vessels that feed the brain and tightly controls what gets in, keeping most immune cells and large molecules out. In MS, this barrier breaks down. Immune cells that were activated elsewhere in the body manage to cross the vessel walls and enter the central nervous system, where they trigger a local inflammatory response that damages myelin and the nerve fibers beneath it. This breach is one of the earliest abnormalities detected in MS brains and goes hand in hand with the release of inflammatory signaling molecules called cytokines.1PubMed. Role of the blood-brain barrier in multiple sclerosis
The barrier doesn’t simply collapse everywhere at once. It becomes selectively more permeable in certain spots, which is why MS lesions show up as scattered patches rather than uniform damage. Inflammatory signals loosen the junctions between the cells that form the barrier, allowing waves of immune cells to migrate through. Once inside, those cells encounter myelin proteins they mistakenly identify as foreign threats, and the attack begins in earnest.
What Happens When Myelin Is Stripped Away
Myelin is the insulating sheath that wraps around nerve fibers in segments, allowing electrical signals to jump rapidly from one gap to the next. When the immune system attacks myelin, it doesn’t use just one weapon. Both the adaptive immune system (T cells and B cells that learn to recognize specific targets) and the innate immune system (first-responder cells like macrophages and resident brain immune cells called microglia) contribute to the damage. These cells release enzymes that break down proteins, inflammatory cytokines, and toxic molecules like nitric oxide, all of which chew through myelin and harm the cells that produce it.2Neurology. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis Microglia, in particular, can stay activated for extended periods, and this chronic activation has been linked to the ongoing neurodegeneration seen in progressive forms of the disease.3Frontiers in Neurology. Microglia in the context of multiple sclerosis
When myelin is lost, nerve signals slow down or fail altogether. An intact nerve fiber can transmit signals at high speed because the impulse leaps between the gaps in myelin. Strip the myelin away and the signal has to crawl along the bare fiber, requiring far more energy and often arriving too late or not at all. This is why MS symptoms can fluctuate so dramatically: partial demyelination may slow a signal just enough to cause weakness or numbness, while more severe loss can block it completely.
To compensate, demyelinated nerve fibers can redistribute sodium channels along stretches of fiber that were previously insulated and didn’t need them. This redistribution can partially restore signal conduction, which helps explain why people with MS sometimes recover function after a relapse.4PubMed Central. Changed distribution of sodium channels along demyelinated axons But this workaround comes at a steep metabolic cost, and that cost is where the deeper damage begins.
The Energy Crisis Inside Exposed Nerves
A demyelinated nerve fiber has to work much harder to transmit signals. Those extra sodium channels demand enormous amounts of energy to keep ions flowing in the right directions. The cell’s energy factories, mitochondria, struggle to keep up. When energy production falls short, ion pumps fail, and calcium floods into the nerve fiber. Calcium overload is toxic. It triggers a self-destruct process that degrades the internal skeleton of the nerve and eventually kills it. This mechanism helps explain why MS transitions from a disease of relapses and recoveries into one of steady, irreversible decline.5PubMed. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
There is a twist that researchers have only recently appreciated. Myelin doesn’t just insulate nerve fibers; it also supplies them with metabolic support. The cells that produce myelin, oligodendrocytes, actively shuttle nutrients and energy substrates to the axons they wrap around. In a healthy brain, this partnership keeps nerves alive. But in an inflammatory environment, that dependency becomes a liability. Research has shown that the myelin sheath itself increases the risk of nerve fiber degeneration during an autoimmune attack, challenging the long-held assumption that myelin is purely protective.6Nature Neuroscience. Myelin insulation as a risk factor for axonal degeneration in autoimmune demyelinating disease In other words, the very structure that makes fast signaling possible also makes the nerve more vulnerable when things go wrong.
Why Epstein-Barr Virus Matters
For decades, researchers noticed that nearly everyone with MS had been infected with the Epstein-Barr virus, the common virus behind mononucleosis. A landmark study involving millions of military personnel tracked people over years and found that EBV infection is the trigger for developing MS.7PubMed. Epstein-Barr virus and multiple sclerosis Infection is necessary, but it’s far from sufficient on its own. More than 95% of people worldwide carry EBV, yet only a tiny fraction develop MS. So the virus sets the stage, but other factors determine who actually gets the disease.
One key mechanism is molecular mimicry. A specific protein made by EBV, called EBNA1, contains short stretches of amino acids that look strikingly similar to proteins found in the brain. Researchers have identified three separate regions within EBNA1 that mimic portions of molecules involved in brain cell adhesion and structure. When the immune system mounts a response against EBNA1, the antibodies and T cells it produces can cross-react with these brain proteins, essentially mistaking your own nervous system for the virus.8PubMed Central. Multiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis Antibodies against EBNA1 are found in nearly 100% of MS patients before they ever develop clinical symptoms, suggesting this misdirected immune response is present from very early on.
Genetics, Latitude, and Other Risk Factors
Whether EBV’s molecular mimicry actually leads to disease depends heavily on your genetic makeup. The strongest genetic link involves a gene called HLA-DRB1*1501, which encodes a protein that presents fragments of other molecules to the immune system. This particular variant has been consistently associated with MS across nearly all populations studied, and people who carry it appear to be better at presenting myelin-derived fragments to T cells, effectively making autoimmune attack more likely.9PubMed Central. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations More than 200 other genetic variants have been linked to MS risk, most of them related to immune function, but HLA-DRB1*1501 remains the single biggest genetic contributor.
Geography also plays a role. MS is more common the farther you live from the equator, and this gradient tracks closely with sunlight exposure. Less sunlight means less vitamin D synthesis in the skin and altered melatonin production, both of which influence immune regulation. Moving beyond roughly 37 degrees latitude in either direction tips the balance toward lower vitamin D and higher melatonin, a combination that may create a more permissive environment for autoimmune activity.10PubMed Central. Melatonin and vitamin D, two sides of the same coin, better to land on its edge to improve multiple sclerosis Smoking, obesity during adolescence, and low vitamin D levels are all established environmental risk factors that appear to stack on top of genetic susceptibility.
The Gut Connection
An area of growing interest is the gut microbiome. The trillions of bacteria in your intestines influence immune development and regulation far beyond the digestive tract. In MS, evidence is accumulating that shifts in microbial communities can affect disease through several converging routes: they influence the integrity of both the gut lining and the blood-brain barrier; they shape how T cells and B cells behave; some microbial metabolites can cross into the brain and directly affect microglia, astrocytes, and the cells responsible for making myelin; and gut bacteria communicate with the brain through the vagus nerve.11PubMed Central. The Gut Microbiome in Multiple Sclerosis Whether microbiome-targeted treatments could meaningfully alter MS progression remains an open question, but the biological plausibility is strong enough that clinical trials are underway.
How Inflammation Becomes Smoldering
Early in the disease, MS tends to follow a relapsing-remitting pattern: attacks come and go, and the brain can partially recover between them. But over time, something changes. The dominant type of inflammation shifts from acute, peripherally driven flares to a smoldering, self-sustaining process inside the central nervous system.12PubMed Central. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis This second type of inflammation is already present even in early-stage MS but gradually becomes the dominant driver as the disease progresses and the patient ages.
One of the most striking features of this transition is the formation of ectopic lymphoid follicles in the meninges, the membranes surrounding the brain. These are essentially small, self-organized immune hubs that form inside the central nervous system, allowing B cells and T cells to mature and mount immune responses without needing signals from the rest of the body. They’re found in the meninges of roughly 40% of progressive MS cases examined after death and are associated with more severe cortical damage and faster clinical decline.13PubMed Central. Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models These follicles tend to sit right next to large areas of cortical damage, suggesting that inflammatory molecules diffusing out of them are actively harming nearby brain tissue.14Brain. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
This compartmentalized inflammation helps explain why treatments that work well for relapsing MS, most of which act by reducing the traffic of immune cells into the central nervous system from the bloodstream, become less effective in progressive disease. Once the immune system has set up shop inside the brain itself, blocking the front door matters less.
Why the Brain Struggles to Repair Itself
The brain does have a built-in repair mechanism. Cells called oligodendrocyte progenitor cells can, in principle, mature into new myelin-producing oligodendrocytes and rewrap exposed nerve fibers. This process, remyelination, is most active in early disease and is the reason many people recover substantially after their first few relapses. But in chronic MS lesions, remyelination largely stalls.
For years, researchers focused on the idea that progenitor cells were present in lesions but stuck in an immature state, unable to differentiate into functioning oligodendrocytes. Studies of chronic MS lesions did confirm that this differentiation block is a major reason repair fails.15Brain. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis But newer findings have complicated the picture. Some active lesions contain surviving mature oligodendrocytes that may contribute to remyelination on their own, while many chronic lesions simply don’t have enough oligodendrocyte-lineage cells of any kind. Drugs designed to push progenitor cells to differentiate have shown limited clinical benefit so far, suggesting that the repair problem isn’t just about one bottleneck.16Brain. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier? Ongoing inflammation, scarring by astrocytes, and the loss of the nerve fibers themselves all conspire to make repair increasingly difficult as the disease progresses.
How Treatments Map Onto the Disease Process
Modern MS therapies are designed to interrupt specific steps in the cascade described above. One class of drugs, the S1P receptor modulators (fingolimod, siponimod, ozanimod, and others), works by trapping immune cells in lymph nodes so they never reach the bloodstream and therefore can’t migrate to the brain. These drugs prevent immune cells from leaving lymph nodes, reducing the number of circulating lymphocytes available to cross the blood-brain barrier.17Molecular Pharmacology. S1P1 Modulator-Induced Gαi Signaling and β-Arrestin Recruitment Are Both Necessary to Induce Rapid and Efficient Reduction of Blood Lymphocyte Count In Vivo
Another major category targets B cells directly. Anti-CD20 antibodies such as ocrelizumab, ofatumumab, and rituximab selectively destroy B cells and certain T cells that carry the CD20 marker. These drugs prevent relapses, reduce the appearance of new brain lesions on MRI, and slow disability progression in relapsing MS.18PubMed Central. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic B-cell-depleting therapy is also the first treatment approach shown to protect against disability worsening in primary progressive MS, the form of the disease that lacks clear relapses and has historically been the hardest to treat.19PubMed Central. B-cell Therapy for Multiple Sclerosis: Entering an era The success of these drugs was itself a surprise, because MS had long been considered primarily a T-cell disease. The dramatic effectiveness of B-cell depletion forced a rethinking of how important B cells are in driving and sustaining the autoimmune response.
When B cells repopulate after treatment, they come back looking different: less mature and more activated than before depletion.20PubMed Central. B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis Understanding this reconstitution pattern is an active area of research, because it may help doctors decide how often to re-dose and whether the timing of retreatment matters for long-term safety.
Tracking Nerve Damage With a Blood Test
One of the most practical advances in recent years is the ability to measure nerve damage through a simple blood draw. Neurofilament light chain is a structural protein found inside nerve fibers. When axons are damaged, neurofilament spills into the cerebrospinal fluid and eventually into the bloodstream, where it can be measured. Levels of this protein in the blood correlate with acute axonal damage even at the earliest stages of MS lesion formation.21PubMed Central. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study
Elevated neurofilament levels reflect ongoing inflammatory nerve damage and can predict disease activity over the following few years.22Brain. The potential of serum neurofilament as biomarker for multiple sclerosis For patients and their doctors, this means a blood test taken during a routine office visit can signal whether the disease is active beneath the surface, even when MRI scans look stable or symptoms haven’t obviously worsened. Neurofilament is increasingly being used in clinical trials as a measure of treatment effectiveness and is making its way into routine clinical care, though it’s not specific to MS; any condition that damages nerves can raise levels.23PubMed Central. Assessment of axonal injury in multiple sclerosis: combined analysis of serum light-chain neurofilaments and diffusion tensor imaging
When MS Begins in Childhood
About 3 to 5% of MS cases begin before age 18. Pediatric-onset MS tends to be more inflammatory early on, with higher relapse rates in the first years compared to adult-onset disease. A large study of over 12,000 people with MS found that children took longer to reach major disability milestones from the time of their diagnosis, but they reached those milestones at a younger age than adults did, simply because the clock started sooner.24Neurology. Long-term disability progression of pediatric-onset multiple sclerosis A higher relapse rate in the first five years and a progressive course from the outset were the strongest predictors of faster disability accumulation in children. Recovery from the very first relapse, on the other hand, was associated with a slower trajectory.
Children with MS also face the added challenge of disease activity during critical periods of brain development. The developing brain has greater capacity for repair and plasticity, which may explain the longer time to disability milestones, but the long-term consequences of repeated immune attacks on a still-maturing nervous system remain an area of concern and active research.
What Charcot Saw Under the Microscope
The disease was first formally described in the 1860s by Jean-Martin Charcot, who examined brain tissue from patients with what he called “sclérose en plaques.” Using microscopic sections, Charcot identified three distinct zones in MS lesions: the periphery, the transition zone, and the center. He was already pointing to the importance of the supportive cells in the brain, the “névroglie” or neuroglia, describing them as star-shaped cells with thin, branching processes.25PubMed Central. One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease It’s striking that many of today’s research frontiers, including the role of astrocytes and microglia in sustaining damage, the layered structure of lesions, and the interplay between inflammation and scarring, trace directly back to observations Charcot made with 19th-century equipment. The basic architecture he described still holds up. What has changed is our understanding of the living processes that create and maintain those structures, and the growing ability to intervene before the damage becomes permanent.